Veracyte, Inc.

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
21.72 USD +2.65% Intraday chart for Veracyte, Inc. +0.51% -21.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating MT
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating MT
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell MT
Transcript : Veracyte, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors CI
Veracyte Closes $70 Million C2i Genomics Acquisition MT
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc. CI
Transcript : Veracyte, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023 CI
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million. CI
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Veracyte Says New Data Backs Utility of Decipher Genomic Classifier to Treat, Manage Prostate Cancer MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating MT
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook MT
Earnings Flash (VCYT) VERACYTE Reports Q3 Revenue $90.1M, vs. Street Est of $84.4M MT
Transcript : Veracyte, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023 CI
Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023 CI
Goldman Sachs Cuts Veracyte's Price Target to $32 From $37, Keeps Buy Rating MT
Chart Veracyte, Inc.
More charts
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
21.72 USD
Average target price
31.67 USD
Spread / Average Target
+45.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Veracyte, Inc. - Nasdaq
  4. News Veracyte, Inc.
  5. Scotiabank Initiates Veracyte at Sector Outperform Rating With $33 Price Target